Navigation Links
Cancer drug brings relief to patients of Crohn’s Diseas

Researchers have discovered that the use of the drug sargramostim,// also known as Leukine, have helped the patients of Crohn’s disease recover totally from their symptoms. The drug sargramostim is generally used for treating cancer patients who are going through chemotherapy.

Crohn’s disease is the condition that causes inflammation of the small intestine. This can cause pain and diarrhea. It is difficult to diagnose, as its symptoms are similar to other intestinal disorders like irritable bowel syndrome etc. this condition may run in families. The condition is also called ileitis or enteritis.

The drug sargramostim is typically used to increase the recovery of the white blood cells that may drop during the chemotherapy administered to treat patients suffering from cancer. The drug helps the patient gain in immunity to fight outside germs.

Traditionally it is believed that Crohn’s disease is an over activation of the immune system and treatment comprised of giving medication to the patients that will suppress immunity. With the new treatment, there seems to be a total turn in the opposite direction of not lowering but increasing the immune system and allow the body to fight its own battls.
'"/>




Page: 1

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... 2017 , ... While EHR data has revolutionized the nursing ... workstation designed to reduce nursing fatigue while enhancing productivity. Based on field experience ... lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. , Nurses ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... VA (PRWEB) , ... February ... ... FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 ... What are the critical reimbursement questions manufacturers should be asking before selecting ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... February 17, 2017 ... ... Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017  BioDigital, Inc., creators of the ... their 3D body mapping technology with eClinicalWorks, a ... integration will be used to capture and present ... the human body. BioDigital pilots show using a ... also increasing the precision of clinical annotations compared ...
(Date:2/16/2017)... , Feb. 16, 2017 Absorption Systems, ... and medical devices, is pleased to announce that its ... been selected as a winner of the 2017 Executive ... Magazine and recognizes driven executives for their creative ... ethic. The awards ceremony and celebration is on March ...
(Date:2/16/2017)... DaVita Inc. (NYSE: DVA ) today ... 2016. Net income attributable to DaVita Inc. ... $158 million, or $0.80 per share and $880 million, or ... attributable to DaVita Inc. for the quarter and year ended ... $192 million, or $0.98 per share, and $789 million, or ...
Breaking Medicine Technology: